| Identification | Back Directory | [Name]
Benzo[b]thiophene-3-carbonitrile, 2-amino-4-[(4aS)-8-chloro-10-fluoro-2,3,4,4a,5,6-hexahydro-12-oxo-3-(1-oxo-2-propen-1-yl)-1H,12H-pyrazino[2,1-d][1,5]benzoxazocin-9-yl]- | [CAS]
2649788-45-2 | [Synonyms]
KRAS G12C inhibitor 18
Benzo[b]thiophene-3-carbonitrile, 2-amino-4-[(4aS)-8-chloro-10-fluoro-2,3,4,4a,5,6-hexahydro-12-oxo-3-(1-oxo-2-propen-1-yl)-1H,12H-pyrazino[2,1-d][1,5]benzoxazocin-9-yl]- | [Molecular Formula]
C25H20ClFN4O3S | [MOL File]
2649788-45-2.mol | [Molecular Weight]
510.97 |
| Hazard Information | Back Directory | [Uses]
KRAS G12C inhibitor 18 is a potent and orally active KRAS G12C inhibitor. Anti-tumor activities[1]. | [in vivo]
KRAS G12C inhibitor 18 exhibits a dose dependent inhibiton of pERK and active KRas after a single dose treatment from 12.5 to 100 mg/kg at 8 hours[1].
KRAS G12C inhibitor 18 (30 mg/kg; p.o.; twice daily) exhibits anti-tumor growth activity in lung cancer H358 xenograft mouse model[1]. | [IC 50]
KRas G12C | [References]
[1] Serge Louis Boulet, et al. Kras g12c inhibitors. WO2021118877A1. |
|
|